Clinical Trials

500 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06524544 2026-05-27

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

320 enrolled

Carcinoma, Transitional Cell

NCT07461454 2026-05-26

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

376 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT04826341 2026-05-22

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

35 enrolled

Other solid neoplasmThoracic

HRD Cancer

NCT06963905 2026-05-22

SIMONE

Phase 1/2 Recruiting

60 enrolled

Triple Negative Breast Neoplasms

NCT05675579 2026-05-20

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

27 enrolled

Breast Neoplasms

NCT06801834 2026-05-20

EVOKE-SCLC-04

695 enrolled

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT07011654 2026-05-20

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

Phase 1/2 Recruiting

31 enrolled

Phase EARLY_PHASE1 Enrolling by invitation

Triple Negative Breast Neoplasms

NCT06204614 2026-05-18

Drug Screening Using IMD in Bladder Cancer

18 enrolled

Muscle Invasive Bladder Urothelial Carcinoma

NCT06431633 2026-05-18

ARIAN

129 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Diseases

NCT03606967 2026-05-13

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

70 enrolled

Triple Negative Breast Neoplasms

NCT04579224 2026-05-13

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

184 enrolled

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07504588 2026-05-13

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

87 enrolled

Gynecologic

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

NCT07582887 2026-05-13

Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response

Recruiting

70 enrolled

Breast Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT03337698 2026-05-12

Morpheus Lung

Phase 1/2 Terminated

314 enrolled 31 charts

Carcinoma, Non-Small-Cell Lung

NCT05089734 2026-05-07

EVOKE-01

603 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung

NCT05601440 2026-05-07

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

484 enrolled

Breast Neoplasms

NCT04647916 2026-05-06

Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Phase 3 Not yet recruiting

44 enrolled

CNS

Brain Neoplasms

NCT07178730 2026-05-06

ADAPT-TN-IV

765 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04434040 2026-05-04

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

40 enrolled

Phase 1 Active not recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT05143229 2026-05-01

ASSET

18 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07134556 2026-05-01

ADJUNCT

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT05633654 2026-04-30

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

1,514 enrolled

Triple Negative Breast Neoplasms

NCT06682728 2026-04-30

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

23 enrolled

Carcinoma, Transitional Cell

NCT04468061 2026-04-29

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

110 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03964727 2026-04-28

TROPiCS-03

227 enrolled 31 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT07328490 2026-04-28

Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer

Phase 1/2 Withdrawn

Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT05581589 2026-04-27

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

Phase 2 Terminated

4 enrolled 13 charts

Urinary Bladder Neoplasms

NCT05327530 2026-04-24

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

256 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06161532 2026-04-24

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

60 enrolled

Carcinoma, Transitional Cell

NCT07339059 2026-04-23

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

35 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04595565 2026-04-22

SASCIA

1,332 enrolled

Triple Negative Breast Neoplasms

NCT03971409 2026-04-17

InCITe

145 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07533123 2026-04-16

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

364 enrolled

Phase 1 Active not recruiting

Triple Negative Breast Neoplasms

NCT04794699 2026-04-09

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

169 enrolled

GenitourinaryThoracic

Urinary Bladder Neoplasms, Lung Neoplasms

NCT05382299 2026-04-06

ASCENT-03

623 enrolled

Triple Negative Breast Neoplasms

NCT04559230 2026-03-30

Sacituzumab Govitecan in Recurrent Glioblastoma

32 enrolled

CNS

Glioblastoma

NCT05226117 2026-03-27

Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer

Phase 2 Completed

44 enrolled

Phase 2 Not yet recruiting

Carcinoma, Transitional Cell

NCT07438600 2026-03-27

TianjinCIH

38 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05884320 2026-03-20

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

30 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT05633667 2026-03-17

VELOCITY-Lung

270 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

792 enrolled

Breast Neoplasms

NCT03547973 2026-03-16

TROPHY U-01

827 enrolled 1 FDA

Phase 1/2 Active not recruiting

Metastatic Urothelial Cancer

NCT04039230 2026-03-16

Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.

75 enrolled

Breast Neoplasms

NCT06133517 2026-03-16

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

70 enrolled

Urothelial Bladder Carcinoma

NCT05833867 2026-03-13

Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer

Phase 1 Recruiting

20 enrolled

Localized Muscle Invasive Bladder Urothelial Carcinoma

NCT06028932 2026-03-05

A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

20 enrolled

Gynecologic

Ovarian Neoplasms

NCT06100874 2026-02-24

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

28 enrolled

Breast Neoplasms

NCT06178588 2026-02-24

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

15 enrolled

Gastrointestinal

Cholangiocarcinoma, Klatskin Tumor

NCT07063212 2026-02-19

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)